Polar Asset Management Partners Inc. Has $581,000 Stake in Tevogen Bio Holdings Inc. (NASDAQ:TVGN)

Polar Asset Management Partners Inc. trimmed its holdings in shares of Tevogen Bio Holdings Inc. (NASDAQ:TVGN) by 20.6% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,577,387 shares of the company’s stock after selling 408,228 shares during the period. Polar Asset Management Partners Inc. owned 0.92% of Tevogen Bio worth $581,000 as of its most recent SEC filing.

Separately, HGC Investment Management Inc. acquired a new stake in Tevogen Bio during the 3rd quarter valued at $82,000.

Insider Activity

In other news, insider Neal Flomenberg sold 1,078,600 shares of Tevogen Bio stock in a transaction on Thursday, October 17th. The stock was sold at an average price of $1.62, for a total value of $1,747,332.00. Following the completion of the sale, the insider now directly owns 4,254,302 shares of the company’s stock, valued at approximately $6,891,969.24. This trade represents a 20.23 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 56.60% of the company’s stock.

Tevogen Bio Stock Up 7.6 %

TVGN stock opened at $1.13 on Friday. The business has a fifty day moving average price of $1.38 and a 200 day moving average price of $0.91. Tevogen Bio Holdings Inc. has a fifty-two week low of $0.26 and a fifty-two week high of $21.09.

Tevogen Bio Profile

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.